Pharmacy denials at external review

• the question matters

  The outcome turns on which question was put to the reviewer: 75.8% on medical necessity (n=3,820) against 59.1% on experimental/investigational (n=301) — a gap of 17 points inside the same treatment class.

• rising

  It has risen over the published record: 31.9% in 2002 against 81.9% in 2025. What drove that is not in this data — the file holds outcomes, not who chose to appeal or how plans changed their own review.

• most-cited standard

  Reviewers named FDA more than any other standard here — 1,817 decisions, which came out at 78.2%. Citing a standard and the outcome share a cause; this is not the effect of naming it.

• concentrated

  43% of these disputes involved endocrine & metabolic alone (n=1,782, 82.3% overturned), so the headline figure for pharmacy is largely that pairing.

California requires each published decision to carry “a detailed case summary that includes the specific standards, criteria, and medical and scientific evidence, if any, that led to the case decision” (Health & Safety Code § 1374.33(h)(1)(K)). These are the elements our extraction found in this class, split by how the decision came out.

Read as description, not instruction. These are patterns in what reviewers wrote, not steps to follow, and no combination of them predicts an outcome. Only codes that cleared the validation gate appear — thirteen did not.

• FDA78.2%1,817
• American Gastroenterological Association84.0%75
• American Headache Society77.8%72
• American Diabetes Association72.5%69
• American College of Rheumatology59.3%59
• American Academy of Neurology83.3%42
• American Academy of Dermatology93.3%30
• MCG / Milliman—24

A rate here is the outcome of decisions that named the authority, not the effect of naming it. Reviewers cite the standard they applied; the citation and the outcome share a cause.

• Endocrine & metabolic82.3%1,782
• CNS & neuromuscular76.7%463
• Digestive & GI80.7%316
• Skin84.5%310
• Immune disorders70.9%292
• Orthopedic & musculoskeletal47.4%175
• Mental health49.2%132
• Genitourinary & kidney69.6%125

Browse all condition classes · Pick your own pair

• Obesity89.2%1,236
• Other65.7%367
• Diabetes77.7%287
• Migraine83.5%164
• Crohn's Disease86.2%123
• Psoriasis87.3%110
• Short Stature39.0%100
• Dermatitis87.6%89

• Medical Necessity75.8%3,820
• Experimental/Investigational59.1%301

Medical-necessity review asks whether the care is needed. Experimental/investigational review asks whether it is likely to be more beneficial than standard therapy — a harder statutory test, and the rates show it.